Sareum (LON:SAR) Announces Quarterly Earnings Results

Sareum (LON:SAR) posted its earnings results on Tuesday. The company reported GBX (0.90) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Sareum Price Performance

Shares of SAR stock opened at GBX 12.52 ($0.16) on Thursday. Sareum has a 12-month low of GBX 10 ($0.13) and a 12-month high of GBX 52.50 ($0.68). The firm has a market capitalization of £15.64 million, a price-to-earnings ratio of -2.96 and a beta of -1.08. The business has a 50 day simple moving average of GBX 17.82 and a 200 day simple moving average of GBX 23.19.

Insider Buying and Selling at Sareum

In related news, insider Stephen Parker bought 84,033 shares of the stock in a transaction on Wednesday, March 26th. The shares were purchased at an average price of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). 5.02% of the stock is owned by company insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.